[
    [
        {
            "time": "2020-04-20",
            "original_text": "复星医药入局新冠疫苗研发，4月下旬进入临床试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "新冠疫苗",
                    "临床试验"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药入局新冠疫苗研发，4月下旬进入临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-03-19",
            "original_text": "恒指收跌2.61%，卫星无线通讯板块领跌",
            "features": {
                "keywords": [
                    "恒指",
                    "下跌",
                    "卫星无线通讯"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融",
                    "科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "恒指收跌2.61%，卫星无线通讯板块领跌",
                "Correlation": 5,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-18",
            "original_text": "辉瑞回应“拒绝向中国提供新冠疫苗”：复星医药已提前拿下中国市场开发和商业权",
            "features": {
                "keywords": [
                    "辉瑞",
                    "新冠疫苗",
                    "复星医药",
                    "中国市场"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "辉瑞回应“拒绝向中国提供新冠疫苗”：复星医药已提前拿下中国市场开发和商业权",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-03-19",
            "original_text": "开盘：恒指小幅低开0.32％ 腾讯业绩增幅超20％涨2.69％",
            "features": {
                "keywords": [
                    "恒指",
                    "低开",
                    "腾讯",
                    "业绩增长"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "科技"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "开盘：恒指小幅低开0.32％ 腾讯业绩增幅超20％涨2.69％",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-18",
            "original_text": "复星医药控股股东增持712万股 七年研发投入增速34.7%难阻业绩低迷",
            "features": {
                "keywords": [
                    "复星医药",
                    "控股股东",
                    "增持",
                    "研发投入",
                    "业绩低迷"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药控股股东增持712万股 七年研发投入增速34.7%难阻业绩低迷",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]